Template:Table of severe drug reactions: Difference between revisions

Line 7: Line 7:
| align="center" style="background:#f0f0f0;"|'''[[Erythroderma]]'''
| align="center" style="background:#f0f0f0;"|'''[[Erythroderma]]'''
|-
|-
| Onset of eruption||2-6 weeks||1-3 weeks||48 hours||1-3 weeks
| '''Onset of eruption'''||2-6 weeks||1-3 weeks||48 hours||1-3 weeks
|-
|-
| Duration of eruption (weeks)||Several||1-3||<1||Several
| '''Duration of eruption (weeks)'''||Several||1-3||<1||Several
|-
|-
| Fever||+++||+++||+++||+++
| '''Fever'''||+++||+++||+++||+++
|-
|-
| Mucocutaneous features||Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions||Bullae, atypical target lesions, mucocutaneous erosions||Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement||Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation
| '''Mucocutaneous features'''||Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions||Bullae, atypical target lesions, mucocutaneous erosions||Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement||Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation
|-
|-
| Lymph node enlargement||+++||-||+||+
| '''Lymph node enlargement'''||+++||-||+||+
|-
|-
| Neutrophils||Elevated||Decreased||Very elevated||Elevated
| '''Neutrophils'''||Elevated||Decreased||Very elevated||Elevated
|-
|-
| Eosinophils||Very elevated||No change||Elevated||Elevated
| '''Eosinophils'''||Very elevated||No change||Elevated||Elevated
|-
|-
| Atypical lymphocytes||+||-||-||+
| '''Atypical lymphocytes'''||+||-||-||+
|-
|-
| Hepatitis||+++||++||++||-
| '''Hepatitis'''||+++||++||++||-
|-
|-
| Other organ involvement||Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis||Tubular nephritis and tracheobronical necrosis||Possible||Possible
| '''Other organ involvement'''||Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis||Tubular nephritis and tracheobronical necrosis||Possible||Possible
|-
|-
| Histological pattern of skin||Perivascular lymphocytcic infiltrate||Epidermal necrosis||Subcorneal pustules||Nonspecific, unless reflecting Sezary syndrome or other lymphoma
| '''Histological pattern of skin'''||Perivascular lymphocytcic infiltrate||Epidermal necrosis||Subcorneal pustules||Nonspecific, unless reflecting Sezary syndrome or other lymphoma
|-
|-
| Lymph node histology||Lymphoid hyperplasia||-||-||No, unless reflecting Sezary syndrome or other malignancy
| '''Lymph node histology'''||Lymphoid hyperplasia||-||-||No, unless reflecting Sezary syndrome or other malignancy
|-
|-
| Mortality (%)||10||5-35||5||5-15
| '''Mortality''' (%)||10||5-35||5||5-15
|}
|}
;AGEP Acute generalized exanthematous pustulosis
;AGEP Acute generalized exanthematous pustulosis

Revision as of 19:15, 17 December 2019

Table of Severe Drug Reactions

Charateristic DRESS SJS/TEN AGEP Erythroderma
Onset of eruption 2-6 weeks 1-3 weeks 48 hours 1-3 weeks
Duration of eruption (weeks) Several 1-3 <1 Several
Fever +++ +++ +++ +++
Mucocutaneous features Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions Bullae, atypical target lesions, mucocutaneous erosions Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation
Lymph node enlargement +++ - + +
Neutrophils Elevated Decreased Very elevated Elevated
Eosinophils Very elevated No change Elevated Elevated
Atypical lymphocytes + - - +
Hepatitis +++ ++ ++ -
Other organ involvement Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis Tubular nephritis and tracheobronical necrosis Possible Possible
Histological pattern of skin Perivascular lymphocytcic infiltrate Epidermal necrosis Subcorneal pustules Nonspecific, unless reflecting Sezary syndrome or other lymphoma
Lymph node histology Lymphoid hyperplasia - - No, unless reflecting Sezary syndrome or other malignancy
Mortality (%) 10 5-35 5 5-15
AGEP Acute generalized exanthematous pustulosis
DRESS drug reaction with eosinophilia and systemic symptoms
SJS Stevens-Johnson syndrome
TEN toxic epidermal necrolysis